Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Analysts

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given a consensus rating of "Buy" by the seven ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.33.

A number of research firms have recently weighed in on CNTX. D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Wednesday, January 15th. JMP Securities began coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 target price on the stock. Finally, Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th.

Context Therapeutics Stock Up 8.8 %

Shares of CNTX traded up $0.08 during trading hours on Friday, reaching $0.96. The company's stock had a trading volume of 101,645 shares, compared to its average volume of 249,728. The company has a 50 day moving average of $1.17 and a two-hundred day moving average of $1.80. The firm has a market cap of $71.75 million, a price-to-earnings ratio of -1.05 and a beta of 2.06. Context Therapeutics has a 1-year low of $0.79 and a 1-year high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. acquired a new position in Context Therapeutics during the 3rd quarter worth $3,689,000. State Street Corp increased its stake in shares of Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company's stock worth $219,000 after purchasing an additional 19,800 shares during the period. Renaissance Technologies LLC lifted its position in shares of Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock worth $131,000 after purchasing an additional 25,300 shares during the last quarter. Clear Harbor Asset Management LLC boosted its stake in Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock valued at $61,000 after purchasing an additional 21,804 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Context Therapeutics in the 3rd quarter valued at approximately $89,000. Institutional investors and hedge funds own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.